IOVA
HEALTHCAREIovance Biotherapeutics Inc
AI Insight
What's Moving IOVA Today?
No stock-specific AI insight has been generated for IOVA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.66$5.63
$4.44
Fundamentals
Market Cap$1.9B
P/E Ratio—
EPS$-0.92
Dividend Yield—
Dividend / Share—
ROE-47.5%
Profit Margin-123.9%
Debt / Equity—
Trading
Volume18.0M
Avg Volume (10D)—
Shares Outstanding446.5M
IOVA News
25 articles- Iovance (IOVA) Surges 9.4% on Regulatory NodYahoo Finance·Jun 24, 2026
- Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool·Jun 23, 2026
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)Yahoo Finance·Jun 19, 2026
- Iovance Biotherapeutics Inc (IOVA) Earnings Forecast: Future EPS & Revenue Growth EstimatesTradingKey·Jun 18, 2026
- H.C. Wainwright Remains a Buy on Iovance Biotherapeutics (IOVA)Insider Monkey·Jun 16, 2026
- Amtagvi Approval Boosted Iovance Biotherapeutics, Inc. (IOVA), But Can the Rally Last?Yahoo Finance·Jun 13, 2026
- Iovance Biotherapeutics (IOVA) Advances Next-Generation TIL Pipeline With FDA Clearance for IOV-5001Yahoo Finance·Jun 10, 2026
- Iovance Biotherapeutics, Inc. (IOVA) a Top Penny Stock to Buy on Amtagvi Strong AdoptionYahoo Finance·Jun 7, 2026
- A Look At Iovance Biotherapeutics (IOVA) Valuation After Australian Conditional Approval For AmtagviYahoo Finance UK·Jun 7, 2026
- Is Iovance Biotherapeutics, Inc. (IOVA) One of the Most Shorted Small-Cap Stocks to Buy Now?Yahoo Finance·Jun 6, 2026
- Iovance Biotherapeutics (IOVA) Gets Australia Nod for Amtagvi, Climbs 15%Yahoo Finance·Jun 5, 2026
- Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in AustraliaYahoo Finance·Jun 3, 2026
- Iovance Stock Has Been Hammered. Is This the Buying Opportunity Aggressive Investors Have Been Waiting For?Motley Fool·Jun 2, 2026
- Does FDA Clearance for IOV-5001 TIL-IL12 Trial Change The Bull Case For Iovance Biotherapeutics (IOVA)?Yahoo Finance·Jun 1, 2026
- Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001Yahoo Finance·Jun 1, 2026
- IBRX Stock Outlook After Q1 Results and a New FDA ReviewYahoo Finance·May 29, 2026
- ImmunityBio: Anktiva Explained and What Comes NextYahoo Finance·May 29, 2026
- AGEN vs. IOVA: Which Cancer Biotech Stock Has More Upside Potential?Yahoo Finance·May 28, 2026
- Soft Tissue Sarcoma with Lung Metastases Market Set to Expand Across the 7MM During the Forecast Period (2026-2036) with Advancing Targeted and Cellular Therapies | DelveInsightYahoo Finance·May 26, 2026
- Assessing Iovance Biotherapeutics (IOVA) Valuation After Strong Recent Share Price MomentumYahoo Finance·May 23, 2026
- Iovance Biotherapeutics to Present at Upcoming ConferenceYahoo Finance·May 21, 2026
- This Beaten-Down Growth Stock Could Soar 165%, According to Wall StreetThe Motley Fool·May 2, 2026
- Is This Biotech Stock the Best Chance to Make a Fortune in Healthcare?The Motley Fool·Apr 10, 2026
- Proleukin Market Research Report 2026-2035: Epidemiology, Pipeline Analysis, Industry Insights and MoreGlobeNewswire Inc.·Apr 1, 2026
- The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First StepBenzinga·Apr 1, 2026
All 25 articles loaded
Price Data
Open$4.00
Previous Close$4.06
Day High$4.52
Day Low$3.99
52 Week High$5.63
52 Week Low$1.66
52-Week Range
$1.66$5.63
$4.44
Fundamentals
Market Cap$1.9B
P/E Ratio—
EPS$-0.92
Dividend Yield—
Dividend / Share—
ROE-47.5%
Profit Margin-123.9%
Debt / Equity—
Trading
Volume18.0M
Avg Volume (10D)—
Shares Outstanding446.5M
About Iovance Biotherapeutics Inc
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company is headquartered in San Carlos, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—